Mounjaro vs Wegovy

Summary: Mounjaro is tirzepatide approved for type 2 diabetes. Wegovy is semaglutide approved for chronic weight management. Tirzepatide produces more weight loss in head-to-head data, but Wegovy is the on-label weight loss choice and the one insurance will actually pay for.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

The short version: Mounjaro and Wegovy are not interchangeable. Mounjaro is tirzepatide, FDA-approved only for type 2 diabetes. Wegovy is semaglutide, FDA-approved for chronic weight management. If your goal is weight loss and you want a drug your insurance will cover on-label, Wegovy is the answer. If your goal is the largest possible weight loss from a GLP-1 and you do not mind that it is being used off-label for that purpose, tirzepatide wins the head-to-head trial. The on-label tirzepatide product for weight loss is called Zepbound, not Mounjaro. That distinction matters more than most comparison articles admit.

This page walks through what each drug actually is, what the trials say, what the side effects look like in practice, what the math is at the pharmacy counter, and what switching between them involves.

The single most important fact: indication

Mounjaro and Wegovy have different approved uses, and the FDA cares about this even if marketing copy blurs it together.

So the strict comparison is: Mounjaro is the type 2 diabetes brand of tirzepatide. Wegovy is the obesity brand of semaglutide. They share a once-weekly subcutaneous injection format and they share a drug class adjacent enough that the side effects overlap heavily, but the labels point at different patient populations.

If a clinician is prescribing tirzepatide for weight loss in a non-diabetic patient, the on-label choice is Zepbound, not Mounjaro. Some prescribers still write Mounjaro for weight loss when Zepbound is short or expensive. That is the off-label gray zone, and it is the source of most of the insurance denials you read about online.

The molecules

Both drugs are once-weekly subcutaneous injectables. Both slow gastric emptying, blunt appetite, and improve glycemic control. The difference is how many receptors they hit.

Semaglutide (Wegovy, Ozempic, Rybelsus) is a single GLP-1 receptor agonist. It mimics the gut hormone glucagon-like peptide-1, which triggers insulin release after meals, slows stomach emptying, and signals satiety to the brain. Wegovy is dosed at 2.4 mg weekly at the maintenance phase, with a five-step titration from 0.25 mg over 16 weeks ^[4]. A higher 7.2 mg dose was approved in 2026 under the brand Wegovy HD.

Tirzepatide (Mounjaro, Zepbound) is a dual GIP and GLP-1 receptor agonist. GIP, glucose-dependent insulinotropic polypeptide, is a second incretin hormone that semaglutide does not touch. Activating both receptors appears to drive larger reductions in body weight and HbA1c than activating GLP-1 alone. Tirzepatide maintenance doses are 5, 10, or 15 mg weekly with a step-up every four weeks from 2.5 mg ^[3].

Different mechanism, different ceiling.

The trial that settled the weight loss question: SURMOUNT-5

SURMOUNT-5 is the only adequately powered head-to-head trial of tirzepatide and semaglutide for obesity. Published in NEJM in 2025, it randomized 751 adults with obesity but without diabetes to either tirzepatide titrated to the maximum tolerated dose (10 or 15 mg) or semaglutide titrated to the maximum tolerated dose (1.7 or 2.4 mg), both weekly for 72 weeks ^[1].

The result: tirzepatide produced a mean weight loss of 20.2%. Semaglutide produced 13.7%. That is a 6.5 percentage point gap in favor of tirzepatide. Put another way, the tirzepatide arm lost roughly 50% more body weight than the semaglutide arm over the same period. The difference was statistically and clinically significant, and it held up across the secondary endpoints (proportion of patients reaching 10%, 15%, 20%, and 25% weight loss).

These numbers map to roughly Zepbound versus Wegovy in real practice. Tirzepatide is tirzepatide regardless of the brand name on the box, and semaglutide is semaglutide. The molecules are what the trial tested. The brand labels are administrative.

For context, the original STEP 1 trial of semaglutide 2.4 mg, published in 2021, found a mean weight loss of 14.9% over 68 weeks in adults with obesity ^[2]. The SURMOUNT-1 trial of tirzepatide 15 mg, published in 2022, found 22.5% over 72 weeks ^[5]. Those are separate trials with different populations, so the head-to-head comparison from SURMOUNT-5 is the cleaner number to cite.

Side effects: more alike than different

The side effect profiles of tirzepatide and semaglutide overlap heavily. Both are GLP-1 based, both slow gastric emptying, and both produce the same recognizable gut symptoms when you titrate. The most common reactions in both pivotal trials were:

• Nausea (most common; 25 to 45% of patients depending on dose)
• Diarrhea
• Constipation
• Vomiting
• Abdominal pain
• Decreased appetite (which is the desired effect, but it counts as an adverse event in trial reports)
• Injection-site reactions
• Fatigue

Severity is typically mild to moderate and clusters around dose increases. The biology is straightforward: when you push the dose up, the gut takes a few weeks to adapt to the new level of gastric slowing. Most people who quit a GLP-1 in the first two months quit during a titration step.

In SURMOUNT-5, treatment discontinuation due to adverse events was similar between groups, roughly 6% on tirzepatide and 8% on semaglutide ^[1]. So the larger weight loss with tirzepatide did not come at the cost of a meaningfully worse tolerability profile in non-diabetic adults at maximum tolerated doses.

Both drugs carry an FDA boxed warning for thyroid C-cell tumors, based on a finding in rodent studies. The clinical relevance in humans is unproven, but the warning means anyone with a personal or family history of medullary thyroid carcinoma or MEN 2 should not take either drug ^[3][4]. Both also carry warnings for pancreatitis, gallbladder disease, acute kidney injury secondary to dehydration, and worsened diabetic retinopathy in patients with pre-existing retinopathy.

Cost and insurance: where Wegovy currently wins

List prices as of early 2026:

The sticker price favors Mounjaro slightly, but insurance coverage favors Wegovy by a wide margin for weight loss. Commercial plans that cover weight-loss drugs at all tend to cover Wegovy on-label and refuse Mounjaro because the diagnosis on the prescription does not match the FDA-approved indication. Medicare Part D historically did not cover any weight-loss drug, though Wegovy's cardiovascular indication has cracked that open for patients with established heart disease ^[4]. Mounjaro is covered by most plans for type 2 diabetes, which is the entire reason a small industry of off-label Mounjaro prescribing for non-diabetic patients exists in the first place.

If insurance denies both, the practical comparison shifts to LillyDirect tirzepatide vials at ~$349 for the 2.5 mg dose versus NovoCare semaglutide at a comparable price. Both manufacturers now sell single-dose vials at a discount to the branded pen list price, which is how cash-pay patients afford a year of treatment.

Compounded versions of both drugs exist in pharmacy gray markets, but tirzepatide and semaglutide both came off the FDA shortage list in 2024, which means 503A compounding pharmacies can no longer mass-produce them. Anything still being sold as "compounded semaglutide" or "compounded tirzepatide" through telehealth in 2026 is operating in narrower legal territory than it was two years ago.

Switching: Wegovy to Mounjaro and back

Patients switch between these drugs for three reasons: insurance forced the switch, tolerability was bad on one, or efficacy plateaued on one and the prescriber wants to try the other class.

Switching from Wegovy to Mounjaro

This is the more common direction, because it is the move you make when 13.7% mean weight loss is not enough and you want the 20.2% ceiling. The conversion is not 1:1 because the drugs hit different receptors.

A reasonable bridge protocol most prescribers use:

1. Take your last Wegovy dose. Wait the standard one-week interval.
2. Start Mounjaro at the 2.5 mg starting dose, not at a dose chosen to match your prior Wegovy dose. The 2.5 mg titration step exists for tolerability, and skipping it does not pay off. Even patients who were maxed out on Wegovy 2.4 mg are restarted at tirzepatide 2.5 mg, because tirzepatide-naive guts still need the adaptation period.
3. Step up by 2.5 mg every four weeks as tolerated.

There is no formal FDA-recommended dose conversion chart between semaglutide and tirzepatide, and prescribers who publish unofficial ones tend to anchor on appetite suppression rather than milligram-equivalent dosing. The reason there is no chart is that the molecules are not equivalent on a per-milligram basis at any dose, so a chart would be misleading.

Switching from Mounjaro to Wegovy

Less common, usually driven by insurance. The same logic applies in reverse: stop tirzepatide, wait the one-week interval, restart semaglutide at the 0.25 mg starting dose, titrate every four weeks per the Wegovy schedule.

Expect some weight regain during the transition window, particularly if the gap between drugs runs longer than two weeks. Appetite returns within days of stopping a GLP-1 because the drug is cleared from the system on its half-life schedule (semaglutide's is about seven days, tirzepatide's about five), but the metabolic adaptation that drives long-term weight loss does not pause and resume cleanly.

What about Ozempic and Zepbound?

These two brand names sit inside the Mounjaro versus Wegovy conversation whether you want them to or not.

• Ozempic is semaglutide for type 2 diabetes. Same molecule as Wegovy, lower maximum dose (2.0 mg versus 2.4 mg or 7.2 mg). When people compare "Ozempic for weight loss," they are talking about off-label use of the diabetes brand of semaglutide. The on-label weight loss version is Wegovy.
• Zepbound is tirzepatide for weight loss. Same molecule as Mounjaro, same maximum doses (5, 10, 15 mg). When people compare "Mounjaro for weight loss," they are talking about off-label use of the diabetes brand of tirzepatide. The on-label weight loss version is Zepbound.

So Mounjaro versus Wegovy is functionally the same molecular comparison as Zepbound versus Ozempic, just with the on-label and off-label assignments flipped on each side. Tirzepatide beats semaglutide on weight loss regardless of which brand box the drug ships in.

Cardiovascular and metabolic outcomes beyond weight

Wegovy has a specific FDA indication for reducing the risk of major adverse cardiovascular events in adults with established heart disease and either obesity or overweight, based on the SELECT trial ^[4]. That is a major label win and the reason Wegovy is reaching Medicare patients who could not otherwise access a GLP-1 for weight loss.

Tirzepatide does not yet have a comparable cardiovascular outcomes trial result. The SURPASS-CVOT trial in adults with type 2 diabetes is ongoing and expected to report in 2026 or 2027. Until then, the cardiovascular evidence base for tirzepatide rests on improved metabolic surrogates (HbA1c, blood pressure, lipids, liver fat) rather than hard outcome data.

For metabolic-associated steatohepatitis (MASH), Wegovy was approved in August 2025 based on a trial showing fibrosis improvement. Tirzepatide has strong phase 2 MASH data but no FDA approval for that indication yet.

For obstructive sleep apnea, Zepbound (tirzepatide) was approved in 2024 for moderate to severe OSA in adults with obesity. Wegovy is not approved for OSA.

The pattern: semaglutide has the broader on-label indication coverage, tirzepatide has the larger weight loss number. Both will likely converge over the next two to three years as more outcome trials read out.

Practical decision guide

The cleanest mental model: if you have diabetes, Mounjaro is the right tirzepatide product. If you have obesity, Zepbound is the right tirzepatide product. Wegovy is the right semaglutide product for either indication when weight is the goal. The mix-and-match between Mounjaro and weight loss exists because insurance and supply forced it to exist, not because it is the cleaner clinical choice.

Common questions

Mounjaro vs Wegovy: which one wins for weight loss?

Tirzepatide (Mounjaro's molecule) produced 20.2% mean weight loss in SURMOUNT-5 versus 13.7% for semaglutide (Wegovy's molecule) over 72 weeks. Tirzepatide wins on raw weight loss, but Wegovy is the FDA-approved weight loss product.

Is Mounjaro FDA-approved for weight loss?

No. Mounjaro is approved only for type 2 diabetes. The FDA-approved tirzepatide product for weight loss is Zepbound, which contains the identical active ingredient.

What are the main Wegovy vs Mounjaro side effects?

Both cause nausea, vomiting, diarrhea, constipation, and abdominal pain. Side effect rates were similar in SURMOUNT-5. Both carry boxed warnings for thyroid C-cell tumors. Hypoglycemia risk rises if either is combined with insulin or sulfonylureas.

Mounjaro vs Wegovy cost: which is cheaper?

Mounjaro list price (~$1,094/month) is slightly lower than Wegovy (~$1,349/month). With insurance and manufacturer copay cards both can drop to $0 to $25. Cash-pay vial programs from each manufacturer land around $349 for starting doses.

Mounjaro vs semaglutide: which is better for weight loss?

Tirzepatide outperformed semaglutide in the SURMOUNT-5 head-to-head trial by 6.5 percentage points of body weight loss. If weight loss is the only criterion, tirzepatide is the better molecule.

Is switching from Mounjaro to Wegovy a safe transition?

Yes, when supervised. Stop Mounjaro, wait one week, restart Wegovy at the 0.25 mg starting dose and titrate per the standard Wegovy schedule. Expect appetite to return faster than weight regain.

Is there a switching from Wegovy to Mounjaro dose conversion chart?

No official one exists, because the molecules are not equivalent on a per-milligram basis. The standard approach is to stop Wegovy, wait one week, restart at Mounjaro 2.5 mg, and titrate up every four weeks regardless of your prior Wegovy dose.

Can I take Mounjaro and Wegovy together?

No. They are both GLP-1 receptor agonists and combining them would multiply gastrointestinal side effects and hypoglycemia risk without added benefit. Switch from one to the other; do not stack.

How long does the difference between Mounjaro and Wegovy take to show up on the scale?

Both produce noticeable appetite suppression within the first two weeks. Meaningful weight loss differences between the two molecules emerge by month three and continue widening through month 18, which is when most trials hit their primary endpoint.

If insurance covers Wegovy but not Mounjaro for weight loss, should I push for Mounjaro anyway?

Usually no. Take the covered drug, titrate to the maximum tolerated dose, and reassess at six to nine months. Most patients who reach the full 2.4 mg Wegovy dose and stay on it long enough hit clinically meaningful weight loss. If you plateau below your goal, then revisit tirzepatide via Zepbound rather than Mounjaro.